Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one

Daniela Fenoglio, Alessia Parodi, Rosa Lavieri, Francesca Kalli, Francesca Ferrera, Augusto Tagliamacco, Andrea Guastalla, Maria Giuseppina Lamperti, Mauro Giacomini, Gilberto Filaci

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Peptide540–548, peptide611–626, peptide672–686 and peptide766–780, which are derived from human telomerase, constitute the immunogenic component of the GX301 cancer vaccine. The relative immunogenicity of these peptides is unknown, thus it is unsure whether their combined use offers real advantages over single peptide stimulation. Hence, this study compared the number of specific immune responses and responders to each peptide, as well as to their mixture (meaning the co-presence of the 4 peptides in the same culture well), achieved after ex vivo stimulation of PBMC from 21, HLA-A2+ (n.11) or HLA-A2- (n.10), healthy donors. The study was performed on freshly collected PBMC (T0) and on PBMC stimulated for 10 d with single peptides or their mixture (T1). Peptide-specific immune responses were analyzed by Elispot and cytokine intracellular staining by flow cytometry. The results showed that each peptide induced specific immune responses in some subjects, with different panels of responders among the peptides. Moreover, the numbers of responses and responders to the single peptides or their mixture were comparable. Importantly, the overall number of responders to the 4 peptides was higher than to each single peptide, or to their mixture, both at T0 and T1. These data demonstrate the immunogenicity of each of the 4 GX301 telomerase peptides. Moreover, they show the advantage of multi-peptide over single peptide stimulation, providing a clear support to their combined administration in vaccination protocols. However, the data pose a warning against peptide administration as a mixture due to possible interference phenomena during antigen presentation processes.

Original languageEnglish
Pages (from-to)838-850
Number of pages13
JournalHuman Vaccines and Immunotherapeutics
Volume11
Issue number4
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Cancer Vaccines
Telomerase
Peptides
HLA-A2 Antigen
Antigen Presentation

Keywords

  • Cancer vaccines
  • Cytokine intracellular staining
  • Elispot
  • GX301
  • Immunogenicity
  • Telomerase

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Immunogenicity of GX301 cancer vaccine : Four (telomerase peptides) are better than one. / Fenoglio, Daniela; Parodi, Alessia; Lavieri, Rosa; Kalli, Francesca; Ferrera, Francesca; Tagliamacco, Augusto; Guastalla, Andrea; Lamperti, Maria Giuseppina; Giacomini, Mauro; Filaci, Gilberto.

In: Human Vaccines and Immunotherapeutics, Vol. 11, No. 4, 01.01.2015, p. 838-850.

Research output: Contribution to journalArticle

Fenoglio, D, Parodi, A, Lavieri, R, Kalli, F, Ferrera, F, Tagliamacco, A, Guastalla, A, Lamperti, MG, Giacomini, M & Filaci, G 2015, 'Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one', Human Vaccines and Immunotherapeutics, vol. 11, no. 4, pp. 838-850. https://doi.org/10.1080/21645515.2015.1012032
Fenoglio, Daniela ; Parodi, Alessia ; Lavieri, Rosa ; Kalli, Francesca ; Ferrera, Francesca ; Tagliamacco, Augusto ; Guastalla, Andrea ; Lamperti, Maria Giuseppina ; Giacomini, Mauro ; Filaci, Gilberto. / Immunogenicity of GX301 cancer vaccine : Four (telomerase peptides) are better than one. In: Human Vaccines and Immunotherapeutics. 2015 ; Vol. 11, No. 4. pp. 838-850.
@article{49e4710d9c684e7cb429af0a417ddd65,
title = "Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one",
abstract = "Peptide540–548, peptide611–626, peptide672–686 and peptide766–780, which are derived from human telomerase, constitute the immunogenic component of the GX301 cancer vaccine. The relative immunogenicity of these peptides is unknown, thus it is unsure whether their combined use offers real advantages over single peptide stimulation. Hence, this study compared the number of specific immune responses and responders to each peptide, as well as to their mixture (meaning the co-presence of the 4 peptides in the same culture well), achieved after ex vivo stimulation of PBMC from 21, HLA-A2+ (n.11) or HLA-A2- (n.10), healthy donors. The study was performed on freshly collected PBMC (T0) and on PBMC stimulated for 10 d with single peptides or their mixture (T1). Peptide-specific immune responses were analyzed by Elispot and cytokine intracellular staining by flow cytometry. The results showed that each peptide induced specific immune responses in some subjects, with different panels of responders among the peptides. Moreover, the numbers of responses and responders to the single peptides or their mixture were comparable. Importantly, the overall number of responders to the 4 peptides was higher than to each single peptide, or to their mixture, both at T0 and T1. These data demonstrate the immunogenicity of each of the 4 GX301 telomerase peptides. Moreover, they show the advantage of multi-peptide over single peptide stimulation, providing a clear support to their combined administration in vaccination protocols. However, the data pose a warning against peptide administration as a mixture due to possible interference phenomena during antigen presentation processes.",
keywords = "Cancer vaccines, Cytokine intracellular staining, Elispot, GX301, Immunogenicity, Telomerase",
author = "Daniela Fenoglio and Alessia Parodi and Rosa Lavieri and Francesca Kalli and Francesca Ferrera and Augusto Tagliamacco and Andrea Guastalla and Lamperti, {Maria Giuseppina} and Mauro Giacomini and Gilberto Filaci",
year = "2015",
month = "1",
day = "1",
doi = "10.1080/21645515.2015.1012032",
language = "English",
volume = "11",
pages = "838--850",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Taylor and Francis Inc.",
number = "4",

}

TY - JOUR

T1 - Immunogenicity of GX301 cancer vaccine

T2 - Four (telomerase peptides) are better than one

AU - Fenoglio, Daniela

AU - Parodi, Alessia

AU - Lavieri, Rosa

AU - Kalli, Francesca

AU - Ferrera, Francesca

AU - Tagliamacco, Augusto

AU - Guastalla, Andrea

AU - Lamperti, Maria Giuseppina

AU - Giacomini, Mauro

AU - Filaci, Gilberto

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Peptide540–548, peptide611–626, peptide672–686 and peptide766–780, which are derived from human telomerase, constitute the immunogenic component of the GX301 cancer vaccine. The relative immunogenicity of these peptides is unknown, thus it is unsure whether their combined use offers real advantages over single peptide stimulation. Hence, this study compared the number of specific immune responses and responders to each peptide, as well as to their mixture (meaning the co-presence of the 4 peptides in the same culture well), achieved after ex vivo stimulation of PBMC from 21, HLA-A2+ (n.11) or HLA-A2- (n.10), healthy donors. The study was performed on freshly collected PBMC (T0) and on PBMC stimulated for 10 d with single peptides or their mixture (T1). Peptide-specific immune responses were analyzed by Elispot and cytokine intracellular staining by flow cytometry. The results showed that each peptide induced specific immune responses in some subjects, with different panels of responders among the peptides. Moreover, the numbers of responses and responders to the single peptides or their mixture were comparable. Importantly, the overall number of responders to the 4 peptides was higher than to each single peptide, or to their mixture, both at T0 and T1. These data demonstrate the immunogenicity of each of the 4 GX301 telomerase peptides. Moreover, they show the advantage of multi-peptide over single peptide stimulation, providing a clear support to their combined administration in vaccination protocols. However, the data pose a warning against peptide administration as a mixture due to possible interference phenomena during antigen presentation processes.

AB - Peptide540–548, peptide611–626, peptide672–686 and peptide766–780, which are derived from human telomerase, constitute the immunogenic component of the GX301 cancer vaccine. The relative immunogenicity of these peptides is unknown, thus it is unsure whether their combined use offers real advantages over single peptide stimulation. Hence, this study compared the number of specific immune responses and responders to each peptide, as well as to their mixture (meaning the co-presence of the 4 peptides in the same culture well), achieved after ex vivo stimulation of PBMC from 21, HLA-A2+ (n.11) or HLA-A2- (n.10), healthy donors. The study was performed on freshly collected PBMC (T0) and on PBMC stimulated for 10 d with single peptides or their mixture (T1). Peptide-specific immune responses were analyzed by Elispot and cytokine intracellular staining by flow cytometry. The results showed that each peptide induced specific immune responses in some subjects, with different panels of responders among the peptides. Moreover, the numbers of responses and responders to the single peptides or their mixture were comparable. Importantly, the overall number of responders to the 4 peptides was higher than to each single peptide, or to their mixture, both at T0 and T1. These data demonstrate the immunogenicity of each of the 4 GX301 telomerase peptides. Moreover, they show the advantage of multi-peptide over single peptide stimulation, providing a clear support to their combined administration in vaccination protocols. However, the data pose a warning against peptide administration as a mixture due to possible interference phenomena during antigen presentation processes.

KW - Cancer vaccines

KW - Cytokine intracellular staining

KW - Elispot

KW - GX301

KW - Immunogenicity

KW - Telomerase

UR - http://www.scopus.com/inward/record.url?scp=84938952627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938952627&partnerID=8YFLogxK

U2 - 10.1080/21645515.2015.1012032

DO - 10.1080/21645515.2015.1012032

M3 - Article

AN - SCOPUS:84938952627

VL - 11

SP - 838

EP - 850

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 4

ER -